|
Nov 27
|
Teva Pharmaceutical: Long-Term Cash Cow
|
|
Nov 27
|
Midday movers: Affirm, Amazon, and More
|
|
Nov 27
|
Roku raised to Buy, YPF extends gains following upgrade: 4 big analyst picks
|
|
Nov 17
|
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
|
|
Nov 16
|
50 Most Populated Countries in 2030
|
|
Nov 14
|
Alkermes (ALKS) Proprietary Drugs Aid Growth Amid Competition
|
|
Nov 14
|
TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug
|
|
Nov 13
|
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
|
|
Nov 13
|
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
|
|
Sep 6
|
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
|
|
Sep 6
|
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
|
|
Jun 30
|
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine
|
|
Jun 28
|
Patients Can’t Get Some Lifesaving Drugs. What’s Causing the Shortages.
|